AN OPEN LABEL, SINGLE ARM TRIAL OF IMMUNOTHERAPY WITH AUTOLOGOUS ANTIGEN PRESENTING CELLS LOADED WITH PA2024 (APC8015F) FOR MEN WITH OBJECTIVE DISEASE PROGRESSION ON PROTOCOL D9902 PART B
Latest Information Update: 30 Nov 2023
At a glance
- Drugs Sipuleucel-T (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Dendreon Corporation
- 31 Jan 2012 Results presented at the 2012 Genitourinary Cancers Symposium, according to a Dendreon Corporation media release.
- 17 Feb 2011 Results presented at the 2011 Genitourinary Cancers Symposium.
- 13 May 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.